WaveMan · Form 4
Wahl Bryan insider trades
> Search tickers & screens ⌘K
LIVE

Wahl Bryan insider trades

Wahl Bryan has filed 16 Form 4s with the SEC that we hold, all for Tarsus Pharmaceuticals, Inc. (TARS), as General Counsel. Across all of them we count 0 purchases worth $0 and 17 sales worth $1.7M reported on Form 4. In the last 12 months: 0 purchases ($0) and 3 sales ($850.4K). The largest single trade was a sale of 4,084 shares of Tarsus Pharmaceuticals, Inc. worth $283.5K, dated 2026-03-17. The first filing on our record is dated 2022-03-11 and the latest 2026-03-19.

Tarsus Pharmaceuticals, Inc. (TARS)

General Counsel · 16 filings · 17 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-11-30S, sale reported on Form 41,183$19.5K2022-12-01
2022-12-01S, sale reported on Form 41,164$19.5K2022-12-01
2022-12-02S, sale reported on Form 41,154$19.5K2022-12-06
2023-03-16S, sale reported on Form 4337$4.5K2023-03-17
2023-03-17S, sale reported on Form 4339$4.5K2023-03-21
2023-03-20S, sale reported on Form 4357$4.5K2023-03-21
2023-03-21S, sale reported on Form 4350$4.5K2023-03-23
2023-03-22S, sale reported on Form 4357$4.5K2023-03-23
2023-03-23S, sale reported on Form 4371$4.5K2023-03-23
2023-11-30S, sale reported on Form 48,356$136.3K2023-12-01
2024-03-18S, sale reported on Form 44,436$135.7K2024-03-19
2025-03-18S, sale reported on Form 43,341$154.7K2025-03-20
2025-03-19S, sale reported on Form 43,261$154.6K2025-03-20
2025-03-20S, sale reported on Form 43,084$154.5K2025-03-20
2026-03-17S, sale reported on Form 44,084$283.5K2026-03-19
2026-03-18S, sale reported on Form 44,125$283.4K2026-03-19
2026-03-19S, sale reported on Form 44,231$283.5K2026-03-19
Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1841401) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms